MODIFICATION
Q -- Experimental validation of candidate Alzheimer�s disease treatments identified by multi-omics analyses
- Notice Date
- 2/17/2022 12:08:57 PM
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 621511
— Medical Laboratories
- Contracting Office
- NATIONAL INSTITUTES OF HEALTH NIDA Bethesda MD 20892 USA
- ZIP Code
- 20892
- Solicitation Number
- 75N95022Q00095
- Response Due
- 3/2/2022 1:00:00 PM
- Archive Date
- 03/17/2022
- Point of Contact
- fred Ettehadieh
- E-Mail Address
-
fred.ettehadieh@nih.gov
(fred.ettehadieh@nih.gov)
- Description
- �(i)������� This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. (ii)������� The solicitation number is 75N95022Q00095 and the solicitation is issued as a request for quotation (RFQ). This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13�Simplified Acquisition Procedures; FAR Subpart 13.5� Simplified Procedures for Certain Commercial Items; and FAR Part 12�Acquisition of Commercial Items and is expected to exceed the simplified acquisition threshold.� (iii)������ The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) Number 2022-04, with effective date January 30, 2022. (iv)������ The associated NAICS code 621511 and the small business size standard is $35 million.�� This requirement is full and open with no set-aside restrictions. (v)������� Research in the National Institute on Aging (NIA), Intramural Research Program (IRP) has identified several FDA approved drugs that may target metabolic abnormalities associated with AD and be of utility as effective disease-modifying AD treatments. Repurposing of approved drugs is a promising approach that can accelerate the development of novel AD treatments. In the NIA funded Drug Repurposing for Effective Alzheimer�s Medicines (DREAM) study, NIA is undertaking pharmacoepidemiologic analyses of 20 FDA approved drugs � identified through multi-omics analyses within the NIA IRP � to test whether older individuals exposed to these �candidate AD treatments� are at lower risk of AD.� Following the DREAM study in two ongoing contracts, the NIA is testing a subset of FDA approved drugs in cell culture-based phenotypic screening models and in a well-characterized transgenic AD mouse model. The purpose of this acquisition is to expand these prior studies.� NIA proposes to 1) select additional, promising drug(s) to test whether they ameliorate pathologic changes associated with AD at the cellular level in cell culture-based phenotypic screening models.� In parallel, the NIA will additionally 2) test the most promising drugs as disease modifying AD treatments in in vivo efficacy studies in a well-characterized transgenic AD mouse model. (vi)������ Independently and not as an agent of the Government, the Contractor shall furnish all the necessary services, qualified personnel, material, equipment, and facilities, not otherwise provided by the Government as needed. This requirement is for the following service: Experimental validation of candidate Alzheimer�s disease treatments identified by multi-omics analyses.� Refer to the three (3) Task Orders Statements of Work (SOW) attached to this notice for details and preparation of separate price quotes. (vii)����� The Government anticipates award of one Indefinite Delivery, Indefinite Quantity (IDIQ) contract from this acquisition (IDIQ Statement of Work is attached for reference purposes). The IDIQ ordering period is for three (3) years and is anticipated to begin on/about May 31, 2022.� The Government will issue a total of three (3) separate task orders on a firm fixed-price basis as result of this acquisition.� The anticipated period of performance (POP) of each task order is for 12-months.� �Task Order 1: POP: On/about May 31, 2022-May 30, 2023. �Task Order 2: POP: On/about May 31, 2023-May 30, 2024. �Task Order 3: POP: On/about May 31, 2024-May 30, 2025. (viii)�� The provision at FAR 52.252-1, Solicitation Provisions Incorporated by Reference (Feb�998), applies to this acquisition. This solicitation incorporates one or more solicitation�provisions by reference, with the same force and effect as if they were given in full text.�Upon request, the Contracting Officer will make their full text available. The offeror is�cautioned that the listed provisions may include blocks that must be completed by the�offeror and submitted with its quotation or offer. In lieu of submitting the full text of those provisions, the offeror may identify the provision by paragraph identifier and provide the�appropriate information with its quotation or offer. Also, the full text of a solicitation�provision may be accessed electronically at these addresses:� https://www.acquisition.gov/browse/index/far ��https://www.hhs.gov/grants/contracts/contract-policies-regulations/hhsar/index.html �� ���������������������������������������������������� (End of provision) The following provisions apply to this acquisition and are incorporated by reference: FAR 52.204-7, System for Award Management (Oct 2018) FAR 52.204-16, Commercial and Government Entity Code Reporting (Aug 2020) FAR 52.212-1, Instructions to Offerors-Commercial Items (Nov 2021) FAR 52.212-3, Offeror Representations and Certifications-Commercial Items (Nov 2021) HHSAR 352.239-73, Electronic and Information Technology Accessibility Notice (December 18, 2015) The clause at FAR 52.252-2, Clauses Incorporated by Reference (Feb 1998), applies to this acquisition. This contract incorporates one or more clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. Also, the full text of a clause may be accessed electronically at these addresses: https://www.acquisition.gov/browse/index/far ����https://www.hhs.gov/grants/contracts/contract-policies-regulations/hhsar/index.html � (End of clause) The following clauses apply to this acquisition and are incorporated by reference: FAR 52.204-13, System for Award Management Maintenance (Oct 2018) FAR 52.204-18, Commercial and Government Entity Code Maintenance (Aug 2020) FAR 52.212-4, Contract Terms and Conditions--Commercial Items (Nov 2021) Addendum to this FAR clause applies to this acquisition and is attached. FAR 52.216-18, Ordering (Aug 2020) FAR 52.216-19, Order Limitations (Oct 1995) HHSAR 352.222-70, Contractor Cooperation in Equal Employment Opportunity Investigations (December 18, 2015) HHSAR 352.239-74, Electronic and Information Technology Accessibility (December 18, 2015) The following provisions and clauses apply to this acquisition and are attached in full text.� Offerors MUST complete the provisions at 52.204-24 and 52.204-26 and submit completed copies as separate documents with their quote. FAR 52.204-24, Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment (Nov 2021) FAR 52.204-26, Covered Telecommunications Equipment or Services-Representation (Oct 2020) FAR 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders--Commercial Items (Jan 2022) HHSAR 352.232-71, Electronic Submission of Payment Requests (February 2, 2022) NIH Invoice and Payment Provisions (Feb 2021) (ix)������ The provision at FAR clause 52.212-2, Evaluation � Commercial Items (Nov 2021), applies to this acquisition.� (a) The Government will award a contract resulting from this solicitation to the responsible offeror whose offer conforming to the solicitation will be most advantageous to the Government, price and other factors considered. The following factors shall be used to evaluate offers: (a) technical capability; (b) price; (c) past performance [see FAR 13.106-2(b)(3)]. Technical and past performance, when combined, are significantly more important than price. (b) A written notice of award or acceptance of an offer, mailed or otherwise furnished to the successful offeror within the time for acceptance specified in the offer, shall result in a binding contract without further action by either party. Before the offer�s specified expiration time, the Government may accept an offer (or part of an offer), whether or not there are negotiations after its receipt, unless a written notice of withdrawal is received before award. (x)������� The Offerors to include a completed copy of the provision at FAR clause 52.212-3, Offeror Representations and Certifications-Commercial Items (Nov 2021), with its offer. If the offeror has completed FAR clause 52.212-3 at www.sam.gov, then the offeror does not need to provide a completed copy with its offer. (xi)������ There are no additional contract requirement(s) or terms and conditions applicable to this acquisition. (xii)����� The Defense Priorities and Allocations System (DPAS) are not applicable to this requirement. (xiii)���� Responses to this solicitation must include clear and convincing evidence of the offeror�s capability of fulfilling the requirement as it relates to the technical evaluation criteria. The price proposal must include the labor categories, an estimate of the number of hours required for each labor category, fully loaded fixed hourly rate or each labor category, breakdown and rationale for other direct costs or materials, and the total amount. �Refer to the three (3) Task Orders Statements of Work (SOW) attached to this notice for details and preparation of separate price quotes. The Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. All quotations from responsible sources must be submitted electronically (by email) to Fred Ettehadieh, Contracting Officer, at fred.ettehadieh@nih.gov by the closing date and time of this solicitation, and reference Solicitation number 75N95022Q00095. Fax responses will not be accepted.
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/7dc8eb5994ff496396af9209690f071a/view)
- Place of Performance
- Address: MD, USA
- Country: USA
- Country: USA
- Record
- SN06245425-F 20220219/220217230100 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |